Cargando…

Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy

INTRODUCTION: Hypertrophic cardiomyopathy (HCM) patients with left ventricular (LV) mid-cavity obstruction (LVMCO) often experience severe drug-refractory symptoms thought to be related to intraventricular obstruction. We tested whether ventricular pacing, guided by invasive haemodynamic assessment,...

Descripción completa

Detalles Bibliográficos
Autores principales: Malcolmson, James W., Hughes, Rebecca K., Joshi, Abhishek, Cooper, Jackie, Breitenstein, Alexander, Ginks, Matthew, Petersen, Steffen E., Mohiddin, Saidi A., Dhinoja, Mehul B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350522/
https://www.ncbi.nlm.nih.gov/pubmed/35916371
http://dx.doi.org/10.1177/17539447221108816
_version_ 1784762235739963392
author Malcolmson, James W.
Hughes, Rebecca K.
Joshi, Abhishek
Cooper, Jackie
Breitenstein, Alexander
Ginks, Matthew
Petersen, Steffen E.
Mohiddin, Saidi A.
Dhinoja, Mehul B.
author_facet Malcolmson, James W.
Hughes, Rebecca K.
Joshi, Abhishek
Cooper, Jackie
Breitenstein, Alexander
Ginks, Matthew
Petersen, Steffen E.
Mohiddin, Saidi A.
Dhinoja, Mehul B.
author_sort Malcolmson, James W.
collection PubMed
description INTRODUCTION: Hypertrophic cardiomyopathy (HCM) patients with left ventricular (LV) mid-cavity obstruction (LVMCO) often experience severe drug-refractory symptoms thought to be related to intraventricular obstruction. We tested whether ventricular pacing, guided by invasive haemodynamic assessment, reduced LVMCO and improved refractory symptoms. METHODS: Between December 2008 and December 2017, 16 HCM patients with severe refractory symptoms and LVMCO underwent device implantation with haemodynamic pacing study to assess the effect on invasively defined LVMCO gradients. The effect on the gradient of atrioventricular (AV) synchronous pacing from sites including right ventricular (RV) apex and middle cardiac vein (MCV) was retrospectively assessed. RESULTS: Invasive haemodynamic data were available in 14 of 16 patients. Mean pre-treatment intracavitary gradient was 77 ± 22 mmHg (in sinus rhythm) versus 21 ± 21 mmHg during pacing from optimal ventricular site (95% CI: −70.86 to −40.57, p < 0.0001). Optimal pacing site was distal MCV in 12/16 (86%), RV apex in 1/16 and via epicardial LV lead in 1/16. Pre-pacing Doppler-derived gradients were significantly higher than at follow-up (47 ± 15 versus 24 ± 16 mmHg, 95% CI: −37.19 to −13.73, p < 0.001). Median baseline NYHA class was 3, which had improved by ⩾1 NYHA class in 13 of 16 patients at 1-year post-procedure (p < 0.001). The mean follow-up duration was 4.6 ± 2.7 years with the following outcomes: 8/16 (50%) had continued symptomatic improvement, 4/16 had symptomatic decline and 4/16 died. Contributors to symptomatic decline included chronic atrial fibrillation (AF) (n = 5), phrenic nerve stimulation (n = 3) and ventricular ectopy (n = 1). CONCLUSION: In drug-refractory symptomatic LVMCO, distal ventricular pacing can reduce intracavitary obstruction and may provide long-term symptomatic relief in patients with limited treatment options. A haemodynamic pacing study is an effective strategy for identifying optimal pacing site and configuration.
format Online
Article
Text
id pubmed-9350522
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-93505222022-08-05 Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy Malcolmson, James W. Hughes, Rebecca K. Joshi, Abhishek Cooper, Jackie Breitenstein, Alexander Ginks, Matthew Petersen, Steffen E. Mohiddin, Saidi A. Dhinoja, Mehul B. Ther Adv Cardiovasc Dis Original Research INTRODUCTION: Hypertrophic cardiomyopathy (HCM) patients with left ventricular (LV) mid-cavity obstruction (LVMCO) often experience severe drug-refractory symptoms thought to be related to intraventricular obstruction. We tested whether ventricular pacing, guided by invasive haemodynamic assessment, reduced LVMCO and improved refractory symptoms. METHODS: Between December 2008 and December 2017, 16 HCM patients with severe refractory symptoms and LVMCO underwent device implantation with haemodynamic pacing study to assess the effect on invasively defined LVMCO gradients. The effect on the gradient of atrioventricular (AV) synchronous pacing from sites including right ventricular (RV) apex and middle cardiac vein (MCV) was retrospectively assessed. RESULTS: Invasive haemodynamic data were available in 14 of 16 patients. Mean pre-treatment intracavitary gradient was 77 ± 22 mmHg (in sinus rhythm) versus 21 ± 21 mmHg during pacing from optimal ventricular site (95% CI: −70.86 to −40.57, p < 0.0001). Optimal pacing site was distal MCV in 12/16 (86%), RV apex in 1/16 and via epicardial LV lead in 1/16. Pre-pacing Doppler-derived gradients were significantly higher than at follow-up (47 ± 15 versus 24 ± 16 mmHg, 95% CI: −37.19 to −13.73, p < 0.001). Median baseline NYHA class was 3, which had improved by ⩾1 NYHA class in 13 of 16 patients at 1-year post-procedure (p < 0.001). The mean follow-up duration was 4.6 ± 2.7 years with the following outcomes: 8/16 (50%) had continued symptomatic improvement, 4/16 had symptomatic decline and 4/16 died. Contributors to symptomatic decline included chronic atrial fibrillation (AF) (n = 5), phrenic nerve stimulation (n = 3) and ventricular ectopy (n = 1). CONCLUSION: In drug-refractory symptomatic LVMCO, distal ventricular pacing can reduce intracavitary obstruction and may provide long-term symptomatic relief in patients with limited treatment options. A haemodynamic pacing study is an effective strategy for identifying optimal pacing site and configuration. SAGE Publications 2022-08-02 /pmc/articles/PMC9350522/ /pubmed/35916371 http://dx.doi.org/10.1177/17539447221108816 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Malcolmson, James W.
Hughes, Rebecca K.
Joshi, Abhishek
Cooper, Jackie
Breitenstein, Alexander
Ginks, Matthew
Petersen, Steffen E.
Mohiddin, Saidi A.
Dhinoja, Mehul B.
Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy
title Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy
title_full Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy
title_fullStr Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy
title_full_unstemmed Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy
title_short Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy
title_sort therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350522/
https://www.ncbi.nlm.nih.gov/pubmed/35916371
http://dx.doi.org/10.1177/17539447221108816
work_keys_str_mv AT malcolmsonjamesw therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy
AT hughesrebeccak therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy
AT joshiabhishek therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy
AT cooperjackie therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy
AT breitensteinalexander therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy
AT ginksmatthew therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy
AT petersensteffene therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy
AT mohiddinsaidia therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy
AT dhinojamehulb therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy